Vedolizumab is a monoclonal antibody for the treatment of ulcerative colitis and Crohn's disease.
It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1), blocking it, and resulting in gut-selective anti-inflammatory activity.
It is administered through intravenous infusion every 8 weeks.
It has an immunogenicity rate of 4-10%.
Labs that test for drug level:
Labs that test for ADA titre: